Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:APLS NASDAQ:GRFS NASDAQ:SLS NASDAQ:XENE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPLSApellis Pharmaceuticals$41.03$33.19$16.10▼$41.14$5.25B-0.247.54 million shs68.61 million shsGRFSGrifols$7.87+2.7%$8.08$7.39▼$11.14$5.21B0.68743,045 shs535,768 shsSLSSELLAS Life Sciences Group$7.29+3.0%$5.09$1.39▼$7.80$1.32B2.246.69 million shs8.89 million shsXENEXenon Pharmaceuticals$53.71-1.3%$56.30$28.19▼$63.95$5.26B0.65942,069 shs676,957 shsThe 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPLSApellis Pharmaceuticals0.00%+0.02%+0.32%+90.22%+135.13%GRFSGrifols+2.74%+0.90%-10.06%-17.59%+1.42%SLSSELLAS Life Sciences Group+2.97%+38.86%+39.66%+99.18%+347.24%XENEXenon Pharmaceuticals-1.25%-3.71%-10.03%+28.92%+77.32%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPLSApellis Pharmaceuticals$41.03$33.19$16.10▼$41.14$5.25B-0.247.54 million shs68.61 million shsGRFSGrifols$7.87+2.7%$8.08$7.39▼$11.14$5.21B0.68743,045 shs535,768 shsSLSSELLAS Life Sciences Group$7.29+3.0%$5.09$1.39▼$7.80$1.32B2.246.69 million shs8.89 million shsXENEXenon Pharmaceuticals$53.71-1.3%$56.30$28.19▼$63.95$5.26B0.65942,069 shs676,957 shsThe 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPLSApellis Pharmaceuticals0.00%+0.02%+0.32%+90.22%+135.13%GRFSGrifols+2.74%+0.90%-10.06%-17.59%+1.42%SLSSELLAS Life Sciences Group+2.97%+38.86%+39.66%+99.18%+347.24%XENEXenon Pharmaceuticals-1.25%-3.71%-10.03%+28.92%+77.32%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPLSApellis Pharmaceuticals 2.09Hold$35.72-12.94% DownsideGRFSGrifols 1.75Reduce$10.0027.06% UpsideSLSSELLAS Life Sciences Group 2.00Hold$10.0037.17% UpsideXENEXenon Pharmaceuticals 3.00Buy$77.0743.49% UpsideCurrent Analyst Ratings BreakdownLatest SLS, XENE, APLS, and GRFS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/15/2026APLSApellis Pharmaceuticals Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral5/12/2026XENEXenon Pharmaceuticals JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$77.00 ➝ $80.005/10/2026XENEXenon Pharmaceuticals Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$69.005/8/2026APLSApellis Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D) ➝ Hold (C-)5/8/2026GRFSGrifols Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D+) ➝ Hold (C-)5/8/2026GRFSGrifols Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell5/8/2026XENEXenon Pharmaceuticals Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$80.00 ➝ $82.005/8/2026XENEXenon Pharmaceuticals Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$80.00 ➝ $78.004/21/2026SLSSELLAS Life Sciences Group Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/17/2026APLSApellis Pharmaceuticals Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOverweight ➝ Equal Weight$26.00 ➝ $41.004/8/2026XENEXenon Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 5/19/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPLSApellis Pharmaceuticals$1.11B4.75$0.21 per share196.33$3.24 per share12.66GRFSGrifols$8.51B0.63$1.45 per share5.41$12.64 per share0.62SLSSELLAS Life Sciences GroupN/AN/AN/AN/A$0.46 per shareN/AXENEXenon Pharmaceuticals$7.50M692.29N/AN/A$7.53 per share7.13Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPLSApellis Pharmaceuticals$22.39M$1.0240.23N/AN/A12.06%39.71%13.20%7/30/2026 (Estimated)GRFSGrifols$454.82M$0.1941.425.430.275.54%6.21%2.39%7/23/2026 (Estimated)SLSSELLAS Life Sciences Group-$26.86M-$0.23N/AN/AN/AN/A-47.12%-42.63%N/AXENEXenon Pharmaceuticals-$345.91M-$4.70N/AN/AN/AN/A-49.23%-46.42%N/ALatest SLS, XENE, APLS, and GRFS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2026Q1 2026SLSSELLAS Life Sciences Group-$0.06-$0.05+$0.01-$0.05N/AN/A5/7/2026Q1 2026APLSApellis Pharmaceuticals-$0.2888$0.15+$0.4388$0.15$208.91 million$268.30 million5/7/2026Q1 2026XENEXenon Pharmaceuticals-$1.17-$1.17N/A-$1.17$1.36 millionN/A3/19/2026Q4 2025SLSSELLAS Life Sciences Group-$0.0633-$0.05+$0.0133-$0.05N/AN/A2/26/2026Q4 2025XENEXenon Pharmaceuticals-$1.20-$1.31-$0.11-$1.31N/AN/A2/24/2026Q4 2025APLSApellis Pharmaceuticals-$0.39$0.47+$0.86-$0.45$199.28 million$199.91 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAPLSApellis PharmaceuticalsN/AN/AN/AN/AN/AGRFSGrifols$0.141.78%N/A73.68%N/ASLSSELLAS Life Sciences GroupN/AN/AN/AN/AN/AXENEXenon PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPLSApellis Pharmaceuticals0.873.633.16GRFSGrifols1.162.470.85SLSSELLAS Life Sciences GroupN/A17.2217.22XENEXenon PharmaceuticalsN/A27.7927.79Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPLSApellis Pharmaceuticals96.29%GRFSGrifolsN/ASLSSELLAS Life Sciences Group17.38%XENEXenon Pharmaceuticals95.45%Insider OwnershipCompanyInsider OwnershipAPLSApellis Pharmaceuticals6.50%GRFSGrifols0.19%SLSSELLAS Life Sciences Group1.20%XENEXenon Pharmaceuticals4.07%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPLSApellis Pharmaceuticals770128.02 million119.70 millionOptionableGRFSGrifols25,247680.58 million679.28 millionOptionableSLSSELLAS Life Sciences Group10186.03 million183.80 millionNot OptionableXENEXenon Pharmaceuticals21096.67 million92.73 millionOptionableSLS, XENE, APLS, and GRFS HeadlinesRecent News About These CompaniesDNB Asset Management AS Acquires 23,750 Shares of Xenon Pharmaceuticals Inc. $XENEMay 18 at 3:44 AM | marketbeat.comXenon Pharmaceuticals Inc. (XENE) Presents at Bank of America Global Healthcare Conference 2026 TranscriptMay 14, 2026 | seekingalpha.comStock Traders Buy High Volume of Put Options on Xenon Pharmaceuticals (NASDAQ:XENE)May 14, 2026 | marketbeat.comXenon Pharmaceuticals (NASDAQ:XENE) Price Target Raised to $80.00 at JPMorgan Chase & Co.May 12, 2026 | marketbeat.comEquities Analysts Set Expectations for XENE Q2 EarningsMay 12, 2026 | marketbeat.comState of New Jersey Common Pension Fund D Sells 35,973 Shares of Xenon Pharmaceuticals Inc. $XENEMay 12, 2026 | marketbeat.comA Look At Xenon Pharmaceuticals (XENE) Valuation After Phase 3 X TOLE2 Success And Extended Cash RunwayMay 11, 2026 | finance.yahoo.comDid Positive X-TOLE2 Data and a Major Cash Raise Just Shift Xenon Pharmaceuticals' (XENE) Investment Narrative?May 11, 2026 | finance.yahoo.comNan Fung Trinity HK Ltd. Has $10.17 Million Stock Holdings in Xenon Pharmaceuticals Inc. $XENEMay 10, 2026 | marketbeat.comXenon Pharmaceuticals Q1 Earnings Call HighlightsMay 9, 2026 | marketbeat.comXenon Highlights Positive Phase 3 Azetukalner Seizure DataMay 8, 2026 | theglobeandmail.comXenon Q1 earnings match estimates, pipeline development in focusMay 8, 2026 | msn.comXenon Pharmaceuticals (NASDAQ:XENE) Stock Price Expected to Rise, Royal Bank Of Canada Analyst SaysMay 8, 2026 | marketbeat.comNeedham & Company LLC Cuts Xenon Pharmaceuticals (NASDAQ:XENE) Price Target to $78.00May 8, 2026 | marketbeat.comXenon Pharmaceuticals Inc. (XENE) Q1 2026 Earnings Call TranscriptMay 8, 2026 | seekingalpha.comXenon Pharmaceuticals: Q1 Earnings SnapshotMay 7, 2026 | finance.yahoo.comXenon (XENE) Q1 2026 Earnings TranscriptMay 7, 2026 | finance.yahoo.comXenon Pharmaceuticals (NASDAQ:XENE) Issues Quarterly Earnings ResultsMay 7, 2026 | marketbeat.comXenon Reports Q1 2026 Financial Results and Provides Business UpdateMay 7, 2026 | globenewswire.comXenon MRI Advances as a Cardiopulmonary Biomarker Platform at ATS 2026May 7, 2026 | globenewswire.comXenon Pharmaceuticals Inc. (NASDAQ:XENE) Receives Consensus Rating of "Buy" from BrokeragesMay 6, 2026 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSLS, XENE, APLS, and GRFS Company DescriptionsApellis Pharmaceuticals NASDAQ:APLS$41.03 0.00 (0.00%) As of 05/14/2026Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.Grifols NASDAQ:GRFS$7.87 +0.21 (+2.74%) Closing price 05/18/2026 04:00 PM EasternExtended Trading$7.87 0.00 (-0.01%) As of 08:07 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease. It markets diagnostic testing equipment, reagents, and other equipment; biological products; manufactures and sells plasma to third parties; and involves in research activities, as well as markets pharmaceutical products for hospital pharmacies. In addition, the company offers Yimmugo PID, an immunology drug; and Yimmugo ITP, a hematology drug. Further, it develops Xembify Pre-filled syringes, FlexBag, and Prolastin vials; Xembify Biweekly dosing, Prolastin-C, Fostamatinib2, and VISTASEAL which are in Phase IV development stage; Xembify, Albumin 20% and 5%, Fibrinogen, Trimodulin, Cytotec pregnancy, and AMBAR-Next in Phase III development stage; and AKST4290 that is in Phase II clinical development. Additionally, it offers recIG, Alpha-1 AT in non-cystic fibrosis bronchiectasis, ATIII, GIGA 2339, GIGA564, and OSIG. It has collaboration agreements with Canadian Blood Services for the processing of other plasma-derived products and with GIANT; and GigaGen to develop recombinant polyclonal immunoglobulin therapies. The company was founded in 1909 and is headquartered in Barcelona, Spain.SELLAS Life Sciences Group NASDAQ:SLS$7.29 +0.21 (+2.97%) Closing price 05/18/2026 04:00 PM EasternExtended Trading$7.32 +0.03 (+0.40%) As of 08:33 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.Xenon Pharmaceuticals NASDAQ:XENE$53.71 -0.68 (-1.25%) Closing price 05/18/2026 04:00 PM EasternExtended Trading$53.60 -0.11 (-0.20%) As of 08:06 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Dillard’s Posted a Huge Earnings Beat—So Why Did the Rally Fade? Why Trump’s Amazon Stock Sale May Not Matter at All Why Applied Optoelectronics Stock May Be Near a Turning Point Is Everspin Technologies the Next AI Edge Breakout? 5 Robotics Stocks to Watch as Physical AI Builds Momentum Willing and Abel: Berkshire's New CEO Makes Huge Portfolio Changes in Q1 Peloton Stock Gives Back Gains After Upbeat Earnings Report 3 Infrastructure Stocks Fueling the Data Center Building Boom Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
